Home Newsfeeds NeuroSense Therapeutics Says On Dec. 13, 2022 FDA Provided Comment That Data Submitted Do Not Support Entire Paradigm Study Duration, Says Co. Responded To Comment Providing Additional Supportive Data, Justification For Study Duration

NeuroSense Therapeutics Says On Dec. 13, 2022 FDA Provided Comment That Data Submitted Do Not Support Entire Paradigm Study Duration, Says Co. Responded To Comment Providing Additional Supportive Data, Justification For Study Duration

-SEC Filing

byMichael Horton

December 15, 2022

1 minute read

-SEC Filing

Here’s How Much You Would Have Made Owning Netflix Stock In The Last 20 Years

By Benzinga Insights

November 4, 2:30 PM

Netflix (NASDAQ:NFLX) has outperformed the market over the past 20 years by 28.28% on an annualized basis producing an average annual return of 35.7%. Currently, Netflix has a market capitalization of $115.24 billion.

NFLX

News

Why NetEase (NTES) Stock Is Falling

By Henry Khederian

May 30, 12:07 PM

NetEase Inc (NASDAQ: NTES) shares are trading lower by 4.80% to $85.21.

NTES

Trading Chalkboards For Checkouts: How One Teacher’s Shift To Costco Paid Off

By Bibhu Pattnaik

October 2, 12:55 PM

A former teacher, after dedicating nearly a decade to the classroom, decided to switch over to retail. After eight years in education, Maggie Perkins felt the mounting pressures of administrative duties. The challenges of teaching during the Covid-19 pandemic pushed her to consider alternative career paths.

AMZN